Surpass, Inc
Surpass, Inc. is a privately held preclinical CRO providing GLP-compliant safety, feasibility, cadaver, and bio-skills training studies for medical device, pharmaceutical, biologic, and combination product developers across two AAALAC-accredited U.S. facilities.
- Company typePrivate
- Founded-
- HeadquartersOsceola, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Surpass, Inc does
Surpass, Inc. is a privately held preclinical contract research organization (CRO) headquartered in Osceola, Wisconsin, with a second facility in Mountain View, California (Surpass-Silicon Valley, LLC, acquired from LyChron in 2013). The company provides GLP-compliant preclinical research services for medical device, pharmaceutical, biologic, and combination product developers, spanning feasibility studies, prototype evaluation, GLP safety studies, human cadaver testing, histopathology and analytical testing, and physician/clinical bio-skills training. Therapeutic area expertise covers cardiac (structural heart and electrophysiology), vascular, neurological, orthopedic/spine, oncology, wound healing, gastrointestinal, urogenital, respiratory, and dermal applications.
Surpass differentiates through AAALAC-accredited facilities in two major U.S. biomedical clusters, a senior scientific and veterinary team with 20–35+ years of industry experience (CEO Dr. Tim Pelura since 2013), and consecutive CRO Leadership Awards from Life Science Leader Magazine in Quality and Regulatory categories (2014, 2015, 2019). The company's digital infrastructure includes the iSurpass Remote Study Monitoring (RSM) system and MySurpass client portal, enabling remote client participation in studies.
The business operates a fee-for-service professional services model with quote-based, NDA-gated pricing. Go-to-market is enterprise field sales targeting medical device companies (primary), pharmaceutical firms, biotechs, and combination product developers, supplemented by content marketing (blog, white papers), industry events (MD&M West, SAWC), and a network of Innovation Award programs at Stanford Biodesign, UCSF CTSI, University of Minnesota Medical Devices Center, and the Rosenman Institute (QB3) that generate early-stage medtech startup pipeline. No public revenue, funding rounds, or valuation are disclosed.
Surpass, Inc firmographics
Firmographics- Name
- Surpass, Inc
- Legal name
- Surpass, Inc.
- Website
- https://surpassinc.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Surpass, Inc. is a privately held preclinical CRO providing GLP-compliant safety, feasibility, cadaver, and bio-skills training studies for medical device, pharmaceutical, biologic, and combination product developers across two AAALAC-accredited U.S. facilities.
- Ownership category
- akta.pro rank
Surpass, Inc industry classification
Industry- Product category
- Preclinical Contract Research Services
- NAICS
- Scientific Research and Development Services (5417), Testing Laboratories and Services (54138)
- akta.pro primary industry
- Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)
- akta.pro secondary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
Keywords
Where Surpass, Inc is headquartered
LocationHeadquarters
- HQ city
- Osceola
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Surpass, Inc business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Others
Revenue model
- Preclinical Research Services: Fee-for-service preclinical research studies including feasibility studies, product development, GLP-compliant safety studies, cadaver testing and training, and physician/clinical bio-skills training for medical devices, pharmaceuticals, biologics, and combination products.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Surpass, Inc product offering
Product offeringCore offering
Surpass is a preclinical contract research organization (CRO) that conducts GLP-compliant preclinical research studies for medical devices, pharmaceuticals, biologics, and combination products. The company delivers feasibility studies, product development support, GLP safety studies, human cadaver testing, histopathology, and physician/clinical bio-skills training from AAALAC-accredited facilities in the Midwest (Osceola, WI) and Silicon Valley (Mountain View, CA).
Product overview
Surpass, Inc is a preclinical contract research organization (CRO) providing comprehensive research services for medical devices, pharmaceuticals, biologics, and combination products. The company operates a unified service platform centered around GLP-compliant preclinical studies, cadaver testing, and physician training, delivered through two AAALAC-accredited facilities (Silicon Valley and Midwest). Core offerings include feasibility studies, product development, GLP safety studies, FDA regulatory assistance, histopathology services, and human cadaver labs. Supporting digital platforms include the iSurpass Remote Study Monitoring system and MySurpass client portal. The company also operates innovation award programs providing in-kind preclinical services to early-stage medtech entrepreneurs at partner institutions.
Differentiator
Problem solved
Functional benefit
Products and services
- Preclinical Research Services for Medical Devices Comprehensive preclinical research services for medical device development, including feasibility studies, product development, GLP safety studies, and physician/clinical training using large in vivo models and human cadavers. Targeted at medical device companies.
- Preclinical Research Services for Pharmaceuticals and Biologics Preclinical contract research for pharmaceutical and biologic products covering proof-of-concept, early feasibility, iterative prototype evaluations, pharmacokinetics (PK), and GLP safety studies. Targeted at pharmaceutical and biotech companies.
- GLP Studies and FDA Assistance Good Laboratory Practice (GLP) compliant preclinical studies for regulatory submissions and IRB approval, with qualified study directors and on-site quality assurance auditing. Targeted at developers needing regulatory-grade preclinical data for FDA submissions.
- Human Cadaver Labs and Testing Human cadaver tissue studies for medical device testing, providing dimensional compatibility assessment, spatial interaction analysis, deliverability evaluation, and device placement testing in human anatomy. Targeted at medical device developers and physicians.
- Physician and Clinical Bio-Skills Training Bioskills training programs using human cadaver models to train physicians on medical device procedures and clinical techniques. Targeted at physicians and clinical staff.
- Histopathology and Analytical Testing Comprehensive histopathology and analytical testing services for preclinical studies, including sample analysis and endpoint assessments. Targeted at preclinical research sponsors.
Companies that use Surpass, Inc
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles4 records
Surpass, Inc technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Surpass, Inc partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, minor and flagship.
- ExponentcoreSurpass partners with Exponent, a scientific and engineering consulting firm, to provide comprehensive human cadaver lab services. Exponent's Biomedical Engineering Laboratories are fully compliant with CFR 21 Part 58 GLP regulations and provide mechanical testing (servo-hydraulic and electromechanical frames), imaging (optical microscopy, fluoroscopy, microCT, ESEM), and device-tissue interface characterization to supplement Surpass' preclinical testing capabilities.
- GraftWorxminorGraftWorx, an emerging medical device company working on 'smart' vascular prosthetics (stents and bypass grafts), won preclinical in-kind services from Surpass as part of the Rosenman Institute's 2015 Innovation Award. Their first product aims to reduce amputations related to vascular prostheses.
- Rosenman Institute (QB3)flagshipSurpass sponsors the Rosenman Institute's Innovation Awards, an initiative of California life science accelerator QB3 that speeds medical device development. Surpass grants in-kind preclinical services to first and second place award recipients to provide initial preclinical proof-of-concept data.
- University of Minnesota Medical Devices CenterflagshipSurpass established a Surpass Innovation Award at the University of Minnesota Medical Devices Center, the first award for an institution in the Midwest. The award provides select Innovation Fellows with initial preclinical proof-of-concept data and support through the preclinical study process and investor due diligence.
- UCSF Clinical and Translational Science Institute (CTSI)flagshipSurpass established a Surpass Innovation Award within UCSF's CTSI Catalyst Awards Program (Medical Devices Track) to support early-stage medtech innovation. Awardees receive their first preclinical proof-of-concept data and support through the entire study process plus investor due diligence assistance.
- Stanford Biodesign ProgramflagshipSurpass established the Surpass Award at Stanford Biodesign to provide early-stage medtech innovators with their first preclinical proof-of-concept data. Surpass supports awardees through the entire preclinical study process and provides assistance during investor due diligence. The first recipient was Torix Medical, working on a device for urinary obstruction related to BPH.
- LyChron, LLC (now Surpass-Silicon Valley, LLC)flagshipSurpass acquired LyChron, LLC, expanding its capacity to serve the medical device and preclinical research community. The California entity operates as Surpass-Silicon Valley, LLC and provides proof-of-concept, feasibility, prototype evaluation, validation, and GLP safety preclinical studies, as well as physician and clinical training and novel disease model development.
Scale indicators3 records
Recent moves6 records
Expansion highlights3 records
Surpass, Inc competitors and assessment
Company assessmentDirect peers
- NAMSA: Medical-device-focused contract research organization providing preclinical, clinical, and regulatory services — a direct competitor in the same medical-device preclinical niche Surpass serves.
- Toxikon (Eurofins Medical Device Testing): Preclinical GLP toxicology and medical device testing CRO (now part of Eurofins) — a direct peer for Surpass' GLP safety assessment and combination-product study business.
- Pacific BioLabs: Independent preclinical CRO focused on GLP toxicology, medical device, and biocompatibility testing for pharma and device sponsors — closely comparable in scale and service mix to Surpass.
- Bionova Scientific: Preclinical CRO providing GLP-compliant services for biologics, pharmaceuticals, and medical devices — a comparable niche CRO competing for similar small-to-mid biotech and medtech sponsors.
- QLab (WuXi AppTec preclinical arm, San Diego): San Diego-based preclinical CRO focused on medical device GLP and combination-product testing under WuXi's umbrella — competes directly with Surpass-Silicon Valley for West Coast medtech sponsors.
Broad incumbents
- Charles River Laboratories: Large global CRO with a dedicated Interventional and Surgical Services / medical device preclinical division — directly overlapping Surpass' core offering and at significantly greater scale (Surpass' CSO previously led CRL's Interventional & Surgical Services Massachusetts division).
- Medpace: Mid-to-large CRO with strong medical device and combination-product clinical/preclinical capabilities, competing with Surpass for sponsor relationships across the device-product lifecycle.
- WuXi AppTec: Global preclinical CRO with broad toxicology, safety assessment, and medical device testing capabilities, offering international scale that Surpass lacks.
- Eurofins Scientific: Global testing-and-CRO conglomerate whose Medical Device division (including Toxikon) competes head-to-head with Surpass in preclinical safety, GLP, and combination-product work.
- Labcorp (incl. Covance, formerly MPI Research): Major CRO with preclinical, central lab, and clinical trial services — a scaled competitor for Surpass' safety assessment and combination-product sponsors.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Surpass, Inc social profiles
Digital presenceSurpass, Inc compliance and trust
Trust signalCompliance2 records
Surpass, Inc financial estimates
Financial estimateRevenue estimate
Valuation estimate
Surpass, Inc leadership team
Management profileNumber of profiles
Profiles8 records
Surpass, Inc subsidiaries and ownership
Company hierarchySubsidiaries1 record
Surpass, Inc funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Surpass, Inc M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Surpass, Inc
What does Surpass, Inc do?
Surpass is a preclinical contract research organization (CRO) that conducts GLP-compliant preclinical research studies for medical devices, pharmaceuticals, biologics, and combination products. The company delivers feasibility studies, product development support, GLP safety studies, human cadaver testing, histopathology, and physician/clinical bio-skills training from AAALAC-accredited facilities in the Midwest (Osceola, WI) and Silicon Valley (Mountain View, CA).
Is Surpass, Inc a public or private company?
Surpass, Inc is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Surpass, Inc founded?
Surpass, Inc was founded in -1. It employs 101 to 250 people.
Where is Surpass, Inc based?
Surpass, Inc is headquartered in Osceola, United States, in the North America region.
How does Surpass, Inc make money?
One revenue line is on record: preclinical Research Services.
Who are Surpass, Inc's main competitors?
Direct peers on record are NAMSA, Toxikon (Eurofins Medical Device Testing), Pacific BioLabs, Bionova Scientific and QLab (WuXi AppTec preclinical arm, San Diego). Broad incumbents are Charles River Laboratories, Medpace, WuXi AppTec, Eurofins Scientific and Labcorp (incl. Covance, formerly MPI Research).
Does Surpass, Inc have an API?
No public API is recorded for Surpass, Inc.
What industry is Surpass, Inc in?
Surpass, Inc's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAC, Toxicology & Safety Assessment CROs (GLP), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417.